Cambridge Antibody Technology (CAT), owned by AstraZeneca, will be folded into MedImmune and will adopt its name. The new MedImmune business unit will unite the resources and expertise from CAT, the pre-existing MedImmune and other biologics activities within the AstraZeneca Group, under the “MedImmune” name. With this structure, AZ has immediately created one of the world’s leading vertically integrated biotechnology businesses, with more than $1.3 billion in revenues in 20...